Authors
Latest:
Dr. Lee on Nanotechnology Combination Therapy in RCCBenjamin R. Lee, MD, chief, Division of Urology, University of Arizona College of Medicine-Tucson Department of Surgery, and director of the Genitourinary Cancer and Disease Oriented Strategic Planning Team, University of Arizona Cancer Center, discusses nanotechnology combination therapy for patients with renal cell carcinoma (RCC).
Latest:
Dr Weinberg on the Prognostic Use of ctDNA Testing in Resected CRCBenjamin Adam Weinberg, MD, discusses the ability of ctDNA-based MRD detection to predict the benefit of adjuvant chemotherapy in resected CRC.
Latest:
Dr. Weksler on Neoadjuvant and Adjuvant Therapy in NSCLCBenny Weksler, MD, FACS, chief, Division of Thoracic Surgery, professor, Surgery, University of Tennessee Health Science Center, Eastridge-Cole Endowed Professor of Thoracic Surgery, West Cancer Center, discusses the role of minimally-invasive surgery in the stages of non–small cell lung cancers (NSCLC).
Latest:
Dr. You on Findings from the TROPHIMMUN Study in Gestational Trophoblastic TumorsBenoit You, MD, PhD, discusses the findings of the phase 2 TROPHIMMUN study which treated chemotherapy-resistant gestational trophoblastic tumors with avelumab.
Latest:
Dr Fox on a Dark Matter–Containing Multivalent Vaccine in Head and Neck CancerBernard A. Fox, PhD, discusses an off-the-shelf multivalent vaccine that contains cancer’s dark matter combined with anti–PD-1 and anti-GITR antibodies in head and neck cancer.
Latest:
Dr Bochner on the Need for Multimodal Approaches in MIBCBernard H. Bochner, MD, FACS discusses genomic complexity and heterogeneity in bladder cancer tumors.
Latest:
Dr. Escudier on Patients Preferring Pazopanib for mRCCDr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.
Latest:
Dr. Rapoport on Rolapitant for the Prevention of CINVBernardo L. Rapoport, MD, chief medical oncologist, The Medical Oncology Center of Rosebank, Johannesburg, South Africa, discusses the utility of rolapitant for preventing chemotherapy-induced nausea and vomiting (CINV).
Latest:
Dr Kasper on the FDA Approval of Nirogacestat in Desmoid TumorsBernd Kasper, MD, PhD, discusses the significance of the FDA approval of nirogacestat for patients with desmoid tumors.
Latest:
Dr. O'Neil on Next Steps for Napabucasin With FOLFIRI and Bevacizumab in CRCBert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the next steps for napabucasin with FOLFIRI and bevacizumab (Avastin) as treatment for patients with colorectal cancer.
Latest:
Dr. O'Neil on Left-Sided Versus Right-Sided CRCBert O'Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses left-sided versus right-sided colorectal cancer (CRC).
Latest:
Dr. O'Neil on Neuroendocrine TumorsBert O’Neil, MD, the Joseph W. and Jackie J. Cusick Professor of Oncology, professor of medicine, and director of the Phase I and Gastrointestinal Oncology Programs at Indiana University, discusses the importance of differentiating between neuroendocrine tumors (NETs).
Latest:
Dr Yuh on the Role of Genetic Factors in Risk Stratification for Prostate CancerBertram Yuh, MD, MISM, MSHCPM, discusses the role of genetic factors, such as BRCA mutations, in the risk stratification of patients with prostate cancer.
Latest:
Dr Tombal on the Pharmacokinetics of Darolutamide Plus Docetaxel in mHSPCBertrand Tombal, MD, PhD, discusses the pharmacokinetics of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer.
Latest:
Dr. DuPree Provides Z11 Trial Takeaway PointsDr. Beth DuPree from Holy Redeemer Health System Provides Z11 Trial Takeaway Points
Latest:
Sotorasib Shows Encouraging Antitumor Activity in Advanced NSCLCThe investigational drug sotorasib demonstrated promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation, an aberration for which no targeted treatment has yet been approved.
Latest:
Essential Components of Survivorship CareAt the 2012 NCCN annual meeting, a panel of oncology nurses discussed the essential components of healthcare for survivors, challenges survivors face, and survivorship program models.
Latest:
Genes Predispose Some Anthracycline Patients to Heart FailureResearchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.
Latest:
Dr. Overmoyer on Inflammatory Triple-Negative Breast CancerBeth Overmoyer, MD, director, Inflammatory Breast Cancer Program, Dana-Farber Cancer Institute, speaks on treatment challenges of inflammatory breast cancer.
Latest:
Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian CancerBeth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.
Latest:
MRI-Guided Radiation Therapy Modernizes Breast Conservation MethodsThe major advance of the MRI-guided radiotherapy system is the ability to visualize the lumpectomy cavity before and during the delivery of each treatment.
Latest:
Addressing Health Inequities in Cancer Screening: Challenges and OpportunitiesExplore critical issues surrounding health disparities in cancer screening, as discussed by experts, and the urgent need to bridge gaps in access, trust, and follow-up care for underserved populations.
Latest:
Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AMLBetty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.
Latest:
Adequate Resources Are Key to Oncology Clinical Trial SuccessWith all the exciting developments occurring in cancer research, community oncology practices that currently do not offer clinical trials to patients may be considering executing a research program.
Latest:
Emerging ADCs in Advanced Endometrial Cancer: Anti-TROP2 and Anti-FR AgentsPanelists discuss recent data on emerging antibody-drug conjugates in advanced and recurrent endometrial cancer, including anti-TROP2 agents like sacituzumab govitecan from the TROPiCS-03 trial, datopotamab deruxtecan from TROPION-PanTumor03, and sacituzumab tirumotecan, as well as anti–folate receptor agents like luveltamab tazevibulin and rinatabart sesutecan, while offering future perspectives and closing thoughts on the evolving role of these agents in the treatment landscape for endometrial cancer.
Latest:
Dr. Santomasso on Managing CNS Toxicity from CAR T-Cell Therapy for B-Cell LymphomaBianca D. Santomasso, MD, PhD, discusses how she prevents central nervous system toxicity due to CAR T-cell therapy for aggressive B-cell lymphoma in her own practice.
Latest:
Future Directions and Unmet Needs in Relapsed/Refractory MCLA panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
